Startup nabs $5.3M to back 2015 launch for connected fertility thermometer, app

Wink--Courtesy of Kindara

Kindara hopes to make conception a bit less fretful for women. It has raised $5.3 million in seed financing for a launch slated for the end of this year of its Wink wireless basal thermometer that connects to a corresponding fertility tracking app. The startup expects the device/app combo will be useful for women both as a tool to ease conception, as well as a means of avoiding it.

The app tracks basal temp in tandem with several other factors that could be relevant to fertility including the consistency of cervical fluid, which is thought to thicken during a fertile window, as well as menstruation date and any other user-identified potentially relevant factors such as travel or scheduling changes.

The device can be pre-ordered via the company site for $79, with the price slated to increase by $50 on September 15.

Women are intended to use the device prior to leaving bed in the morning at roughly the same time daily. The temperature data is wirelessly transmitted to the app to be viewed and analyzed alongside the other data inputs. The process takes 15 seconds, which the company claims is four times faster than a traditional basal thermometer reading.

Kindara also expects to use the financing to finalize Wink manufacturing, as well as to add other products.

"Women want to understand their bodies and use that knowledge to make informed decisions about their reproductive health. The Kindara platform gives them an unprecedented level of insight, support and empowerment when making decisions around achieving or avoiding pregnancy," said Kindara CEO Will Sacks in a statement. "This recent round of funding will allow us to extend our lead in this movement and expand beyond fertility to provide lifetime support for women's health and wellness."

The financing was led by Boston Seed Capital with participation from SOSV, Good Works Ventures, PV Ventures, MENA Venture Investments and 62 Mile Ventures.

"Women's health is important on a global scale," concluded Boston Seed Venture Partner Dave Balter in a statement. "The future of healthcare is personalized, participatory and mobile."

- here is the statement

Suggested Articles

Grail published new data showing that its cancer-screening blood test is now able to spot more than 50 types of the disease and across all stages.

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.